A recent study in JAMA Oncology has highlighted the benefits of screening patients with Li-Fraumeni syndrome using whole-body MRI imaging. The study demonstrates that screening with whole-body MRI enables clinically useful early detection of cancer in TP53 mutation carriers. The … Read More
The previous article outlined how p53 isoforms are changing our view on how TP53 is involved in so many different functions in the cell. Where we used to think there was only one p53 protein doing everything, we now know … Read More
The scientific understanding of TP53 continues to evolve and change – while it’s still known primarily because of its function in tumour suppression, we also know that it is central to how cells respond to an increasingly wide range of … Read More
One of the most important questions for people with LFS is whether there is anything that can be done to reduce the risks of developing cancer. Is there something in diet, exercise or lifestyle that can reduce the risks? One … Read More
One of the most contentious issues for people dealing with Li Fraumeni Syndrome is screening – the active program of checking for cancers before any symptoms become evident. The idea is simple enough – if we can catch cancer before … Read More
A question that crops up again and again is how many people with Li Fraumeni Syndrome (LFS) are there in the UK? While it’s an easy question to ask, it’s not so easy to find an answer. The fact is … Read More
As part of our fund-raising strategy we’ve recently signed up to a service called Give As You Live. It’s a simple idea – basically it’s a web site which you use to access your favourite online shopping sites. Each time … Read More
One of our big research interests at the George Pantziarka TP53 Trust is on active measures to reduce the risk of cancer in people with LFS. To date I have published two papers setting out the biological rationale suggesting that … Read More
The George Pantziarka TP53 Trust has been a supporter of the Off-patent Drugs Bill for some time – writing in support of the Bill and adding our name and logo to a number of public interventions in favour of the … Read More
Colorectal cancer is not normally considered one of the core ‘LFS cancers’ – in fact less than 3% of LFS cancers are colorectal – yet we have gladly out our name to supporting an innovative trial in bowel cancer in … Read More